18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma

Peking University Cancer Hospital & Institute

Status: Unknown

Conditions: Lymphoma, T-Cell, Peripheral

Treatments: Device: 18F-FDG PET/ CT

Study type: Interventional

Funder types: Other

Identifiers

NCT03051581

XW-PTCL-002

Details and patient eligibility

About

The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of PTCL can predict disease progression

Full description

In this study investigators develop a prognostic model based on 18F-FDG PET/CT and test its ability for prognostic value in patients with DLBCL. PET/CT scans evaluation using the liver SUVmax as reference. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold or new 18F-FDG avid lesions. 18F-FDG PET/CT-based prognostic model includes PET/CT image, dominant clinical and pathological prognostic factors to predicting disease progression during chemotherapy or survival in PTCL.

Enrollment: 80 estimated patients

Sex: All

Ages: 12 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• newly diagnosed PTCL
• treated using an anthracycline-containing regimen
• minimal follow-up at 6 months after the completion of first-line treatment
• complete medical history and clinicopathological data

Exclusion criteria

• secondary malignant disease
• serious infection or inflammation (e.g., HIV)
• primary central nervous system lymphoma
• hepatic or renal dysfunction.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

80 participants in 1 patient group

18F-FDG PET/CT-based prognostic model of PTCL

Experimental group

Description:

The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.

Treatment:

Device: 18F-FDG PET/ CT